ADAR1 Capital Management »

Akero Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Akero Therapeutics (AKRO) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Akero Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Akero Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Akero Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $46k 1.8k 25.26
2023-12-31 $374k 16k 23.35

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Akero Therapeutics

Henderson Group
BlackRock
BlackRock
General Atlantic
T. Rowe Price Associates
Vanguard Group
State Street Corporation
Alliancebernstein
Perceptive Advisors
Boxer Capital
Geode Capital Management
Redmile Group
Point72 Asset Management
T. Rowe Price Investment Management
Baker Bros. Advisors

View all funds holding Akero Therapeutics